Bayesian monitoring of clinical trials with failure-time endpoints

被引:16
|
作者
Rosner, GL [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA
关键词
clinical trials; Dirichlet process; Gibbs sampling; survival analysis;
D O I
10.1111/j.0006-341X.2005.031037.x
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
This article presents an aid for monitoring clinical trials with failure-time endpoints based on the Bayesian nonparametric analyses of the data. The posterior distribution is a mixture of Dirichlet processes in the presence of censoring if one assumes a Dirichlet process prior for the survival distribution. Using Gibbs sampling, one can generate random samples from the posterior distribution. With samples from the posterior distributions of treatment-specific survival curves, one can evaluate the current evidence in favor of stopping or continuing the trial based on summary statistics of these survival curves. Because the method is nonparametric, it can easily be used, for example, in situations where hazards cross or are suspected to cross and where relevant clinical decisions might be based on estimating when the integral between the curves might be expected to become positive and in favor of the new but toxic therapy. An example based on an actual trial illustrates the method.
引用
收藏
页码:239 / 245
页数:7
相关论文
共 50 条
  • [21] The Ongoing Evolution of Optimal Clinical Endpoints for Heart Failure Trials
    Krum, Henry
    Hopper, Ingrid
    [J]. JACC-HEART FAILURE, 2015, 3 (08) : 615 - 617
  • [22] Blinded continuous monitoring in clinical trials with recurrent event endpoints
    Friede, Tim
    Haring, Dieter A.
    Schmidli, Heinz
    [J]. PHARMACEUTICAL STATISTICS, 2019, 18 (01) : 54 - 64
  • [23] ENDPOINTS IN CLINICAL TRIALS
    Priker, R.
    [J]. LUNG CANCER, 2009, 64 : S22 - S22
  • [24] Bayesian information fusion method for reliability analysis with failure-time data and degradation data
    Guo, Junyu
    Li, Yan-Feng
    Peng, Weiwen
    Huang, Hong-Zhong
    [J]. QUALITY AND RELIABILITY ENGINEERING INTERNATIONAL, 2022, 38 (04) : 1944 - 1956
  • [25] Clinical trials: Surrogate endpoints or hard endpoints?
    Kuller, LH
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (2A): : 59E - 61E
  • [26] Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: A survey from the Italian National Monitoring Centre for Clinical Trials
    Irene Floriani
    Nicole Rotmensz
    Elena Albertazzi
    Valter Torri
    Marisa De Rosa
    Carlo Tomino
    Fillipo de Braud
    [J]. Trials, 9
  • [27] Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: A survey from the Italian National Monitoring Centre for Clinical Trials
    Floriani, Irene
    Rotmensz, Nicole
    Albertazzi, Elena
    Torri, Valter
    De Rosa, Marisa
    Tomino, Carlo
    de Braud, Fillipo
    [J]. TRIALS, 2008, 9 (1)
  • [28] Use of win time for ordered composite endpoints in clinical trials
    Troendle, James F.
    Leifer, Eric S.
    Yang, Song
    Jeffries, Neal
    Kim, Dong-Yun
    Joo, Jungnam
    O'Connor, Christopher M.
    [J]. STATISTICS IN MEDICINE, 2024, 43 (10) : 1920 - 1932
  • [29] Decongestion in Acute Heart Failure-Time to Rethink and Standardize Current Clinical Practice?
    Bilgeri, Valentin
    Spitaler, Philipp
    Puelacher, Christian
    Messner, Moritz
    Adukauskaite, Agne
    Barbieri, Fabian
    Bauer, Axel
    Senoner, Thomas
    Dichtl, Wolfgang
    [J]. JOURNAL OF CLINICAL MEDICINE, 2024, 13 (02)
  • [30] Real Time Quality Control for Subjective Endpoints in Clinical Trials
    Peng, Y.
    Morinan, G.
    O'Keeffe, J.
    [J]. MOVEMENT DISORDERS, 2020, 35 : S414 - S414